Search / Trial NCT00001402

PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Dec 9, 2002

Trial Information

Current as of December 26, 2024

Completed

Keywords

Dilated Cardiomyopathy Hibernating Myocardium Ischemic Cardiomyopathy Metoprolol Stress Thallium Scintigraphy Congestive Cardiomyopathy Congestive Heart Failure Heart Failure

ClinConnect Summary

Deterioration in left ventricular function, which is characteristic in patients with congestive heart failure, appears to be a multifactorial process. Beta-blockers appear to reverse the deterioration and frequently improve left ventricular function in patients with both ischemic and non-ischemic cardiomyopathies. The mechanism by which beta-blockers improve ejection fraction is not known. Although it is well established that regional flow, function and metabolism may improve after coronary revascularization whether beta-blocker therapy will have similar salutary results in patients with co...

Gender

ALL

Eligibility criteria

  • Left ventricular ejection fraction by radionuclide angiography of less than or equal to 40%.
  • New York Heart Association class II, III or IV symptoms on standard heart failure medications which my include digoxin, diuretics and angiotensin converting enzyme inhibitors for at least one month prior to enrollment.
  • Ischemic cardiomyopathy if enzymes document an MI or 70% or greater stenosis in one major vessel.
  • Dilated cardiomyopathy-if no coronary disease.
  • No pregnant or lactating women.
  • No women of child-bearing age not on proven birth control.
  • No severe hepatic or renal disease.
  • No diabetes mellitus or fasting glucose greater than or equal to 120 mg/dl.
  • No primary valvular heart disease.
  • No PTCA or CABG within 3 months of enrollment.
  • No history of myocardial infarction or unstable angina within past 2 months.
  • No resting heart rate less than 60 bpm.
  • No A-V block greater than 1 degree block without pacemaker.
  • No severe ETOH abuse within 6 months of enrollment.
  • No severe bronchospasm.

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials